Nutritional Intervention With Black Garlic
Clinical Trial to Evaluate the Efficacy of Black Garlic in Reducing Cardiovascular Risk in Subjects With Hypercholesterolemia
1 other identifier
interventional
62
1 country
1
Brief Summary
A controlled clinical intervention study is proposed to determine the effect of black garlic consumption on biomarkers of cardiovascular function and associated pathologies in a healthy population at risk for cardiovascular disease. Black garlic is the result of a fermentation process of common white garlic in which the temperature and humidity are kept constant over a long period of time. Black garlic is particularly rich in phenolic compounds such as S-allylcysteine or S-allyl-mercaptocysteine, with antioxidant action. It also provides vitamin C and other valuable antioxidant substances such as flavonoids.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Sep 2020
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2020
CompletedFirst Submitted
Initial submission to the registry
June 8, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2021
CompletedFirst Posted
Study publicly available on registry
October 18, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
November 30, 2021
CompletedOctober 18, 2021
October 1, 2021
10 months
June 8, 2021
October 15, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Impact on blood pressure
Blood pressure (diastolic, systolic)
changes observed from baseline at day 0 compared to 12 weeks.
Impact on lipid profile
Plasma levels of total cholesterol, HDL, LDL, VLDL (very low-density lipoprotein), triglycerides, apolipoproteins A1 and B.
changes observed from baseline at day 0 compared to 12 weeks.
Secondary Outcomes (9)
Impact on blood cells (Hematology)
changes observed from baseline at day 0 compared to 12 weeks.
evaluation of liver function to determine product safety
changes observed from baseline at day 0 compared to 12 weeks.
Changes in cytokine levels
changes observed from baseline at day 0 compared to 12 weeks.
Changes in chemokine MCP-1 (monocyte chemotactic protein)
changes observed from baseline at day 0 compared to 12 weeks.
Changes in C reactive protein
changes observed from baseline at day 0 compared to 12 weeks.
- +4 more secondary outcomes
Study Arms (2)
Healthy Group,
EXPERIMENTALDaily consumption of 4 cloves of black garlic, not cooked, during 12 weeks
Hypercholesterolemia
EXPERIMENTALDaily consumption of 4 cloves of black garlic, not cooked, during 12 weeks
Interventions
Daily consumption of 4 cloves of black garlic, not cooked, during 12 weeks
Eligibility Criteria
You may qualify if:
- Healthy Group:
- Total blood cholesterol levels of less than 200 mg/dL
- LDL-cholesterol levels of less than 135 mg/dL
- Not suffer from any other pathology.
- No drugs, hormones or dietary supplements, no smoking, no pregnancy, no vegetarianism, etc.
- Cardiovascular Risk Group:
- Total cholesterol levels between 200-300 mg/dL
- LDL-cholesterol levels between 135-175 mg/dL.
- No acute or chronic pathology, except hypercholesterolemia
- No drugs, hormones or dietary supplements, no smoking, no pregnancy, no vegetarianism, etc.).
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Universidad Católica de Murcia (UCAM)
Murcia, 30107, Spain
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Vicedean of Pharmacy Degree
Study Record Dates
First Submitted
June 8, 2021
First Posted
October 18, 2021
Study Start
September 1, 2020
Primary Completion
June 30, 2021
Study Completion
November 30, 2021
Last Updated
October 18, 2021
Record last verified: 2021-10
Data Sharing
- IPD Sharing
- Will not share